Puertas-Neyra, Kevin
Coco-Martin, Rosa M. http://orcid.org/0000-0002-1811-1417
Hernandez-Rodriguez, Leticia A.
Gobelli, Dino
Garcia-Ferrer, Yenisey
Palma-Vecino, Raicel
Tellería, Juan José
Simarro, Maria
de la Fuente, Miguel A.
Fernandez-Bueno, Ivan
Funding for this research was provided by:
Agencia Estatal de Investigación (PID2020-118860RB-I00 /AEI/10.13039 /501100011033)
Article History
Received: 2 February 2024
Accepted: 16 June 2024
First Online: 2 July 2024
Declarations
:
: This study, originally approved under the title: “<i>Estudio molecular del gen PROM1 en pacientes con Distrofias Hereditarias de la Retina y nuevas aproximaciones terapéuticas basadas en la edición genética (PROMedit)</i>” [“Molecular Study of the <i>PROM1</i> Gene in Patients with Hereditary Retinal Dystrophies and New Therapeutic Approaches Based on Gene Editing (PROMedit)”], received ethical approvals from multiple authorities. These approvals include the Research Committee of the Institute for Applied Ophthalmobiology (IOBA) from the University of Valladolid (registration code IOBA-2021–48, registered on November 9, 2021), the Ethics Committee for Medicament Research from East Valladolid (registration code PI 21–2490, registered on December 9, 2021) and the Guarantees Commission of the Carlos III Health Institute (ISCIII) on March 15, 2022 (without registration code). The study adhered to European and Spanish laws and regulations concerning the generation of human iPSC. The generated iPSC lines are registered in the Human Pluripotent Stem Cell Registry (hPSCreg®) under the codes: ESi125-A, ESi126-A and ESi127-A, and they will be deposited at the National Bank of Cell Lines (BNLC) of ISCIII. We received authorization from ISCIII to acquire the iPSC line [FiPS] Ctrl1-Ep6F-5 from BNLC, which was used as a control line. The study followed the principles outlined in the Helsinki Declaration of 1964 (last amended in 2013), data protection law 15/99 enacted on December 13th, and biomedical research law 14/2007 established on July 03. Informed consent was thoroughly explained to and signed by all participating individuals.
: Not applicable.
: This research was partially presented at the German Stem Cell Network (GSCN) meeting 2022 and the European Association for Vision and Eye Research (EVER) meetings in 2022 and 2023. The authors declare no conflicts of interest.
: During the preparation of this work the authors used ChatGPT4 to improve readability and language of the manuscript. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.